Top

International Journal of Clinical Oncology

Published in:

01-12-2018 | Original Article

Novel graded prognostic assessment for colorectal cancer patients with brain metastases

Authors: Byoung Hyuck Kim, Hae Jin Park, Kyubo Kim, Sae-Won Han, Tae-You Kim, Seung-Yong Jeong, Kyu Joo Park, Eui Kyu Chie

Published in: International Journal of Clinical Oncology | Issue 6/2018

Abstract

Purpose

It is important to take into account potential prognostic factors to select patients with brain metastasis from colorectal cancer (CRC) who will benefit from active neurosurgical treatment. Therefore, we experimentally investigated our single institutional data to develop a novel CRC-specific graded prognostic assessment (GPA) and to help clinicians determine the optimal management.

Methods and materials

We retrospectively reviewed the records of 107 patients with brain metastases from CRC who received any kind of treatment in our hospital and had sufficient clinical information.

Results

The median overall survival was 5.2 months, and the 1- and 2-year overall survival rates were 23.7 and 6.6%, respectively. Multivariate analysis revealed that the number of brain metastases ≥ 6, presence of neurologic symptoms, and elevated serum carcinoembryonic antigen (≥ 30 ng/ml) were the independent prognostic factors for poor overall survival, while performance status was not. Based on this, we developed the CRC-specific GPA index and stratified patients into three categories. The median overall survival for patients with GPA scores of 0–0.5, 1.0–1.5, and 2.0–2.5 was 2.3, 4.3, and 12.7 months, respectively (p < 0.001). Surgery or stereotactic radiosurgery ± whole-brain radiotherapy showed a better survival than palliative whole-brain radiotherapy alone in patients with high GPA scores.

Conclusions

We developed a novel CRC-specific GPA index, which could help physicians to stratify patients with brain metastases. Further efforts are needed to validate and improve this index.

Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386. https://doi.org/10.1002/ijc.29210 CrossRef

Jung K-W, Won Y-J, Oh C-M et al (2017) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat 49:292–305. https://doi.org/10.4143/crt.2017.118 CrossRefPubMedPubMedCentral

Christensen TD, Spindler K-LG, Palshof JA et al (2016) Systematic review: brain metastases from colorectal cancer—incidence and patient characteristics. BMC Cancer 16:260. https://doi.org/10.1186/s12885-016-2290-5 CrossRefPubMedPubMedCentral

Christensen TD, Palshof JA, Larsen FO et al (2017) Risk factors for brain metastases in patients with metastatic colorectal cancer. Acta Oncol 56:639–645. https://doi.org/10.1080/0284186X.2017.1290272 CrossRefPubMed

Kim HJ, Huh JW, Jung TY et al (2013) Clinical outcome with gamma-knife surgery or surgery for brain metastases from colorectal cancer. J Clin Neurosci 20:1417–1421. https://doi.org/10.1016/j.jocn.2012.12.020 CrossRefPubMed

Suzuki Y, Yamaguchi T, Matsumoto H et al (2014) Prognostic factors and treatment effects in patients with curatively resected brain metastasis from colorectal cancer. Dis Colon Rectum 57:56–63. https://doi.org/10.1097/01.dcr.0000436998.30504.98 CrossRefPubMed

Michl M, Thurmaier J, Schubert-Fritschle G et al (2015) Brain metastasis in colorectal cancer patients: survival and analysis of prognostic factors. Clin Colorectal Cancer 14:281–290. https://doi.org/10.1016/j.clcc.2015.05.009 CrossRefPubMed

Weltman E, Salvajoli JV, Brandt RA et al (2000) Radiosurgery for brain metastases: a score index for predicting prognosis. Int J Radiat Oncol Biol Phys 46:1155–1161CrossRef

Lorenzoni J, Devriendt D, Massager N et al (2004) Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys 60:218–224. https://doi.org/10.1016/j.ijrobp.2004.02.017 CrossRefPubMed

10.

Sperduto PW, Berkey B, Gaspar LE et al (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70:510–514. https://doi.org/10.1016/j.ijrobp.2007.06.074 CrossRefPubMed

11.

Sperduto PW, Kased N, Roberge D et al (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419–425. https://doi.org/10.1200/JCO.2011.38.0527 CrossRefPubMed

12.

Terret C, Albrand G, Moncenix G et al (2011) Karnofsky performance scale (KPS) or physical performance test (PPT)? That is the question. Crit Rev Oncol Hematol 77:142–147. https://doi.org/10.1016/j.critrevonc.2010.01.015 CrossRefPubMed

13.

Abelson JS, Michelassi F, Sun T et al (2017) Simultaneous resection for synchronous colorectal liver metastasis: the new standard of care? J Gastrointest Surg 21:975–982. https://doi.org/10.1007/s11605-017-3422-1 CrossRefPubMed

14.

Joo JH, Park J-H, Kim JC et al (2017) Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer. Int J Radiat Oncol Biol Phys 99:876–883. https://doi.org/10.1016/j.ijrobp.2017.07.030 CrossRefPubMed

15.

Al Bandar MH, Kim NK (2017) Current status and future perspectives on treatment of liver metastasis in colorectal cancer (review). Oncol Rep 37:2553–2564. https://doi.org/10.3892/or.2017.5531 CrossRefPubMed

16.

Patil CG, Pricola K, Sarmiento JM et al (2017) Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases. Cochrane Database Syst Rev 9:CD006121. https://doi.org/10.1002/14651858.CD006121.pub4 CrossRefPubMed

17.

Yuan X, Liu W-J, Li B et al (2017) A Bayesian network meta-analysis of whole brain radiotherapy and stereotactic radiotherapy for brain metastasis. Medicine (Baltimore) 96:e7698. https://doi.org/10.1097/MD.0000000000007698 CrossRef

18.

Taylor AE, Olver IN, Sivanthan T et al (1999) Observer error in grading performance status in cancer patients. Support Care Cancer 7:332–335CrossRef

19.

Noura S, Ohue M, Shingai T et al (2012) Brain metastasis from colorectal cancer: prognostic factors and survival. J Surg Oncol 106:144–148. https://doi.org/10.1002/jso.23055 CrossRefPubMed

20.

Tanriverdi O, Kaytan-Saglam E, Ulger S et al (2014) The clinical and pathological features of 133 colorectal cancer patients with brain metastasis: a multicenter retrospective analysis of the Gastrointestinal Tumors Working Committee of the Turkish Oncology Group (TOG). Med Oncol 31:152. https://doi.org/10.1007/s12032-014-0152-z CrossRefPubMed

21.

Magni E, Santoro L, Ravenda PS et al (2014) Brain metastases from colorectal cancer: main clinical factors conditioning outcome. Int J Colorect Dis 29:201–208. https://doi.org/10.1007/s00384-013-1781-y CrossRef

22.

Duffy MJ, Lamerz R, Haglund C et al (2014) Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer 134:2513–2522. https://doi.org/10.1002/ijc.28384 CrossRefPubMed

23.

Nozawa H, Ishihara S, Kawai K et al (2017) Brain metastasis from colorectal cancer: predictors and treatment outcomes. Oncology. https://doi.org/10.1159/000478661 CrossRefPubMed

Title: Novel graded prognostic assessment for colorectal cancer patients with brain metastases
Authors: Byoung Hyuck Kim
Hae Jin Park
Kyubo Kim
Sae-Won Han
Tae-You Kim
Seung-Yong Jeong
Kyu Joo Park
Eui Kyu Chie
Publication date: 01-12-2018
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 6/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-018-1329-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods and materials

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2018

Longitudinal changes in the quality of life of oral cancer patients during the perioperative period

Palliative radiotherapy and chemoradiotherapy in stage IVA/B esophageal cancer patients with dysphagia

Serum iron levels increased by cancer chemotherapy correlate the chemotherapy-induced nausea and vomiting

Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments

Prognostic and predictive value of plasma d-dimer levels in patients with small-cell lung cancer

Efficacy of palliative radiotherapy and chemo-radiotherapy for unresectable gastric cancer demonstrating bleeding and obstruction

Keynote webinar | Spotlight on antibody–drug conjugates in cancer